IntelGenx Welcomes Dr. Rajiv Khosla to Its Board
May 24 2011 - 05:00AM
Marketwired
IntelGenx Technologies Corp. (TSX VENTURE: IGX)(OTCBB: IGXT)
("IntelGenx"), is pleased to announce that Dr. Rajiv Khosla has
agreed to join IntelGenx' Board of Directors. Dr. Khosla will bring
a wealth of expertise and experience in oral drug delivery
technology, pharmaceuticals and business development to the Board.
"We are very pleased and excited to have been able to attract
somebody with Dr. Khosla's qualifications, strengths and background
in pharmaceutical business development," Dr. Horst G. Zerbe,
President and Chief Executive Officer of IntelGenx. "Dr. Khosla's
impressive scientific qualifications and background, as well as his
work experience in pharmaceutical transactions, are exceptionally
relevant to our endeavours at IntelGenx and will be invaluable for
the continued success of our pipeline products."
Dr. Khosla expressed his enthusiasm about joining IntelGenx'
Board stating, "I truly believe in the work that IntelGenx is
doing. The Company has several products that are close to
commercialization and continues to pursue unique opportunities for
pharmaceutical drug delivery. It will be my pleasure to serve on
the Board of Directors."
Dr. Khosla was recently named President, Chief Executive Officer
and a member of the board of directors of Orasi Medical, a leading
provider of clinical neurophysiology biomarkers, which is focused
on the industrialization and standardization of
magnetoencephalography (MEG) in central nervous system drug and
therapeutic device development. In January 2011, Dr. Khosla founded
CEUTEC LLC, a private company that offers a full-service of
business development activities to Biotech, Specialty Pharma and
Venture Capital/Private Equity Firms. From September 2005 to
December 2010, Dr. Khosla was Vice President of Business
Development at Biovail Corporation, a Canadian pharmaceutical
company operating internationally. During his tenure at Biovail,
Dr. Khosla successfully led the transaction process for over 75
deal opportunities in a variety of therapeutic areas, including the
central nervous system, dermatology, women's health, cardiovascular
and gastrointestinal, drug delivery, orphan drugs, generics and
pipeline partnerships. From 2003 to 2005, Dr. Khosla held the
position of Vice President and General Manager, Pharmaceutical, of
Sensient Technologies. From 1998 to 2003, Dr. Khosla served as
Senior Business Director, Healthcare at ICI Group, where he managed
a new worldwide healthcare business.
Dr. Khosla possesses a Ph.D. in pharmaceutical science, with a
thesis on Oral Drug Delivery Technology, which he completed in
1987. Additionally, Dr. Khosla holds an Executive MBA from the
Henley Business School in England, a Bachelor of Pharmacy (Honours)
from the University of Nottingham, England and is also a registered
pharmacist in the UK.
The appointment is subject to TSX-V approval.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development
of oral controlled-release products as well as novel rapidly
disintegrating delivery systems. IntelGenx uses its unique multiple
layer delivery system to provide zero-order release of active drugs
in the gastrointestinal tract. IntelGenx has also developed novel
delivery technologies for the rapid delivery of pharmaceutically
active substances in the oral cavity based on its experience with
rapidly disintegrating films. IntelGenx' research and development
pipeline includes products for the treatment of pain, hypertension,
erectile dysfunction, sleep disorders, allergies and depressive
disorders. More information is available about the company at
www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about
IntelGenx' operating results and business prospects that involve
substantial risks and uncertainties. Statements that are not purely
historical are forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and
Section 27A of the Securities Act of 1933, as amended. These
statements include, but are not limited to, statements about
IntelGenx' plans, objectives, expectations, strategies, intentions
or other characterizations of future events or circumstances and
are generally identified by the words "may," "expects,"
"anticipates," "intends," "plans," "believes," "seeks,"
"estimates," "could," "would," and similar expressions. All forward
looking statements are expressly qualified in their entirety by
this cautionary statement. Because these forward-looking statements
are subject to a number of risks and uncertainties, IntelGenx'
actual results could differ materially from those expressed or
implied by these forward looking statements. Factors that could
cause or contribute to such differences include, but are not
limited to, those discussed under the heading "Risk Factors" in
IntelGenx' annual report on Form 10-K for the fiscal year ended
December 31, 2010, filed with the United States Securities and
Exchange Commission and available at www.sec.gov, and also filed
with Canadian securities regulatory authorities and www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Each of the TSX Venture Exchange and OTC Bulletin Board has
neither approved nor disapproved the contents of this press
release.
Contacts: IntelGenx Technologies Corp. Dr. Horst G. Zerbe,
President and CEO +1 514-331-7440 (ext. 201) +1 514-331-0436 (FAX)
horst@intelgenx.com www.intelgenx.com
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Mar 2023 to Mar 2024